Bullish Case: Bull case: ALPHA3 interim MRD clearance (58% vs 16%) and scalable allogeneic CAR-T enable faster commercialization. If safety holds, ALLO could re-rate toward $2.50–$3.50 by year-end 2026 as data refines risk. SPY IV easing supports mild equity risk appetite.

Bearish Case: Bear case: Dilution risk, ongoing losses, and macro biotech headwinds could keep ALLO in low single digits. If interim data disappoints or CRS/ICANS safety issues emerge, the stock could slide below $1.50 by late 2026; SPY risk-off would pressure equities; elevated IV would inflate option costs, hindering hedges. Absence of strategic partnering could erode upside.

Potential Outcomes:

1. Bullish scenario — 20%: ALLO > $3.00 by Nov 2026; triggers: ALPHA3 MRD ≥50%, CRS/ICANS 0-1, no major safety signals.
2. Base-case — 40%: ALLO trades between $1.60–$2.80 through Nov 2026; driver: mixed efficacy and balanced risk.
3. Bearish scenario — 25%: ALLO < $1.50 by Nov 2026; driver: continued dilution risk, higher burn, negative data; triggers: negative MRD, safety signals.
4. Event-driven — 15%: Strategic partnerships or licensing deals; triggers: terms unlocking manufacturing efficiency; price >$3 by late 2026.

May 21, 2026